Avian Coronavirus Variants: IBV Genotypes and Serotypes

Overview and Taxonomy of Avian Coronavirus Variants: IBV Genotypes and Serotypes

Avian infectious bronchitis virus (IBV) represents an exceptionally dynamic pathogen within the Gammacoronavirus genus, characterized by high genetic variability that directly impacts poultry health and global production economics. The virus’s intrinsic ability to undergo rapid mutation and recombination, especially within the S1 subunit of its spike glycoprotein, has led to the emergence of numerous genotypes and serotypes that challenge traditional vaccination and diagnostic strategies [1, 9, 11]. This section delves into an exhaustive analysis of the biological mechanisms, molecular evolution, and epidemiological context that underpin the current taxonomy of IBV variants.

Molecular Basis of IBV Variation

Central to the diversity of IBV is the S1 subunit of the spike protein, which contains key hypervariable regions that govern receptor binding and antigenicity [11]. The naturally error-prone replication machinery of IBV, combined with the extensive recombination events that are common in coronaviruses, produces frequently shifting genetic patterns. Point mutations and genomic recombination, sometimes involving vaccine strains and indigenous field isolates, result in novel mutations that alter both the viral genotype and its serotype [1, 17, 18]. The glycosylation patterns on the spike protein are critical for modulating host cell interaction, as specific N-glycosylation sites in the receptor-binding domain dramatically influence viral attachment and immune recognition [7]. These molecular changes underpin the continual emergence of variants capable of evading previously effective neutralizing antibodies.

Genotypic Classification of IBV

The genotypic landscape of IBV is remarkably heterogeneous. Researchers have categorized IBV into multiple genotypes based on comprehensive phylogenetic analyses of the entire S1 gene. Recent classifications have delineated at least eight major genotypes, within which numerous lineages such as GI-1 (Massachusetts-type), GI-19 (commonly referred to as QX-like), and GI-23 (variant 2) are recognized [15, 16]. GI-1 remains the foundational genotype, historically associated with many live-attenuated vaccines, yet has increasingly been challenged by emergent variants that display markedly different antigenic properties [1, 12]. Genotype GI-19, a dominant variant in many regions, exhibits unique mutations that not only affect tissue tropism but also attenuate vaccine efficacy. Similarly, GI-23 strains have spread extensively in the Middle East and Africa, reflecting a pattern of region-specific evolution that continues to complicate global control measures [5, 15, 20].

Serotypic Complexity and Immune Evasion

While genotypes are defined by genomic sequences, serotypes are determined through antigenic properties, primarily by the presence or absence of neutralizing epitopes on the S1 protein. The identification of serotypes often relies on virus neutralization tests, where differences in the binding capacity of monoclonal antibodies highlight subtle variations in the spike protein’s structure [11, 14]. IBV serotypes are not strictly aligned with genotypic groupings; for instance, isolates from closely related genotypes may exhibit divergent serotypes owing to minimal but immunologically critical amino acid changes in the hypervariable regions [9, 23]. This antigenic diversity leads to serotypes that are poorly cross-neutralized by existing vaccines, thereby reducing the effectiveness of vaccination programs in the field [1, 21]. The phenomenon of protectotyping has even been suggested as a means to group IBV variants according to the breadth of vaccine-induced protection, a strategy that could guide the rational design of polyvalent vaccine formulations [14, 23].

Epidemiological Implications and Global Distribution

The widespread distribution of IBV variants across continents is well documented, with significant regional differences observed in the prevalence of genotypes and serotypes. Surveillance studies from regions such as China, the Middle East, and parts of Africa have consistently highlighted the predominance of variants like QX-like (GI-19) and Variant 2 (GI-23) strains, which emerge despite ongoing vaccination efforts [6, 16, 21]. This epidemiological pattern is a salient reminder of the virus’s capacity for rapid evolution under immune selection pressures, factors that are closely monitored by international organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) [1, 3]. In areas where live poultry trade is extensive and biosecurity measures may be challenged, recombinant IBV variants frequently emerge, underscoring the need for regionally tailored surveillance and vaccine development programs [5, 20, 22].

Taxonomic Challenges and Diagnostic Considerations

The ongoing evolution of IBV has complicated traditional taxonomic frameworks. Molecular methods, such as full-length S1 gene sequencing, provide detailed insights into genetic variation; however, reliance on partial sequences or solely serological approaches can yield misleading interpretations due to the mosaic nature of the IBV genome [9, 14]. The integration of genetic, serologic, and protectotypic data has been suggested as a pathway forward, offering a more holistic and actionable taxonomy that accommodates the rapid pace of IBV evolution [14, 23]. Advanced diagnostic tools, including immunochromatographic assays and biosensor platforms, have been developed to quickly identify IBV variants in the field. These methods, which are endorsed by public health agencies like the CDC and WHO for managing economically significant animal pathogens, facilitate rapid epidemiological assessment and aid in the timely deployment of appropriate vaccination strategies [4, 10, 13].

Implications for Vaccine Development and Disease Management

The intimate link between the genotypic and serotypic diversity of IBV and vaccine efficacy presents major challenges for disease control in the global poultry industry. Traditional vaccines based on the Massachusetts serotype may not confer adequate protection against differently antigenic field variants due to significant sequence divergence and altered receptor binding profiles in the spike protein [1, 2, 8, 19]. Consequently, there is an urgent need for the development of next-generation vaccines that incorporate multiple strains or are tailored to the specific IBV variants circulating in a given region. Such strategies are critical as regulatory bodies like the WOAH continue to emphasize robust surveillance and targeted intervention measures to mitigate the economic impacts of IBV outbreaks worldwide [1, 12, 21].

Molecular Pathogenesis and Viral Evolution in Avian Coronavirus Variants

Avian coronavirus variants, most notably represented by infectious bronchitis virus (IBV), exemplify the intrinsic capacity of RNA viruses to adapt and evolve through complex molecular mechanisms. Central to the molecular pathogenesis of IBV is the spike (S) glycoprotein, particularly its S1 subunit, which mediates host cell receptor binding and governs antigenic specificity. Subtle nucleotide mutations and recurrent recombination events in this region drive not only changes in virus attachment characteristics but also significant antigenic diversity, posing profound challenges for disease control in poultry and economic stability in affected regions [1, 2, 11].

Spike Glycoprotein Modifications and Host Interaction

The S1 protein is a critical determinant of tissue tropism and virulence. Its hypervariable regions (HVRs), which harbor neutralization epitopes, are under intense selective pressure due to the host’s immune response. For instance, variations in HVR1 and HVR2 have been associated with changes in neutralization profiles and cross-protection efficacy of existing vaccines, as demonstrated by site-specific mutations that disrupt monoclonal antibody binding [11]. Glycosylation of the IBV spike protein further modulates its stability and functionality, with specific N-glycosylation sites found to be essential for host receptor binding [7]. This post-translational modification plays a dual role: it not only stabilizes the protein’s conformation but also can shield critical epitopes from immune recognition, thus contributing to immune evasion strategies employed by the virus [7].

Genetic Drift: Mutation, Recombination, and Antigenic Variation

The evolutionary dynamics of IBV are characterized by a high mutation rate, which is typical of RNA viruses lacking proofreading mechanisms during replication. Frequent point mutations and indels in the S1 gene underpin the continuous emergence of variants that elude vaccine-induced immunity. This phenomenon is largely responsible for the considerable genetic heterogeneity observed among circulating IBV strains in diverse geographical regions. Moreover, recombination between co-circulating strains, including between field isolates and vaccine strains, has been documented as another key driver of genetic diversification [8, 14, 17]. Recombination events may occur in multiple genomic regions, including both the structural (S and N genes) and replicase genes, thereby generating chimeric viruses with novel pathogenic and antigenic properties [9, 17, 18]. It is not uncommon for IBV isolates to exhibit mosaic genomes, wherein segments derived from distinct parental strains are joined, leading to the rise of variants with enhanced virulence or altered tissue tropism [12, 17].

Molecular Determinants of Tissue Tropism and Pathogenicity

The interplay between viral genetic alterations and host cellular factors is a cornerstone of IBV pathogenesis. Variations in the S1 protein not only alter receptor-binding efficiency but also can influence the tissue specificity of the virus. For example, IBV variants demonstrate a range of tropisms, from those that predominantly affect the upper respiratory tract to others that possess a broader, multi-organ affinity including the kidneys and reproductive system [24-26]. Detailed studies have shown that the presence or absence of specific mutations in the S1 subunit can determine whether an IBV variant exhibits nephropathogenicity or solely respiratory pathology [8, 25]. Proteomic analysis of infected tissues further reveals that IBV-induced alterations extend beyond viral proteins, with host cell stress proteins and metabolic shifts, such as those involved in the citric acid cycle, being modulated during infection [28, 29].

Immune Pressure and Vaccine Escape

The high degree of antigenic plasticity observed in IBV variants is a direct consequence of immune pressure exerted by both natural infections and vaccination practices. Vaccines based on classical strains, such as the Massachusetts serotype, often fail to confer cross-protection against emerging variants due to substantial differences at the molecular level within the S1 gene [1, 5, 27]. Selective pressure from antibody-mediated neutralization prompts viral populations to favor mutations that diminish antibody binding while maintaining receptor affinity, a phenomenon that has been extensively documented in both experimental and field settings [8, 11, 15]. The emergence of novel genotypes, such as those identified in Kenya and Australia, underscores the virus’s capacity to evolve in response to both host immune defenses and vaccination regimens, thereby necessitating constant surveillance and update of vaccine compositions [1, 5, 12].

Evolutionary Dynamics: Phylogenetic Insights and Regional Diversity

Phylogenetic analyses of IBV S1 gene sequences have been instrumental in unraveling the evolutionary trajectories of different strains. Researchers have classified IBV variants into multiple genotypes and lineages, often revealing distinct geographical patterns of distribution and evolution [9, 16, 30]. The evolution of IBV is not linear; rather, it is punctuated by episodes of rapid diversification triggered by recombination events and accelerated mutation rates. Various studies have elucidated that the virus evolves at a rate of approximately 10^(-5) substitutions per site per year, a relatively rapid pace that contributes to the frequent appearance of new variants [33]. The identification of unique lineages in regions such as sub-Saharan Africa and the Middle East emphasizes the role of local factors, ranging from poultry farming practices to vaccination policies, in shaping the evolutionary dynamics of IBV [5, 20, 31].

The Role of Host-Pathogen Interactions in Viral Adaptation

The viral evolution of IBV cannot be decoupled from the complex interactions with its avian hosts. The evolutionary pressure imposed by the host’s adaptive immune system stimulates the virus to adopt strategies that enhance its survival and dissemination. This includes modifications in epitopes that are key to eliciting a neutralizing antibody response, as well as alterations in viral glycosylation patterns that modulate immune recognition [7, 11]. Moreover, the virus exploits cellular machinery to induce an altered proteomic environment conducive to replication and spread. Studies employing two-dimensional electrophoresis and mass spectrometry have identified several cellular proteins whose expression is modulated during IBV infection, suggesting that the virus may orchestrate a coordinated remodeling of host cell functions to facilitate its life cycle [28]. In this context, understanding the molecular determinants of IBV pathogenicity becomes critical not only for vaccine design but also for the implementation of biosecurity measures as recommended by international authorities such as the World Organisation for Animal Health (WOAH) and the World Health Organization (WHO).

Molecular Epidemiology and Future Challenges

The continuously evolving landscape of IBV variants poses a significant challenge for the poultry industry, as underscored by the frequent outbreaks and vaccine failures recorded across different regions [1, 12, 16]. The emergence of recombinant viruses that carry genetic material from both vaccine and field strains complicates the epidemiological picture, requiring advanced molecular diagnostic tools for accurate detection and classification [14, 17]. In light of these challenges, integrating molecular phylogenetics with traditional pathotyping and protectotyping is increasingly seen as a holistic approach to enhance both our understanding and control of IBV [23]. This integrated approach aligns with current recommendations from global health organizations such as the CDC and FAO, which emphasize the importance of robust surveillance networks and rapid molecular characterization for pathogens with significant economic impact.

Through the convergence of high-resolution molecular techniques, advanced bioinformatics tools, and a detailed understanding of host-pathogen interactions, the field is steadily moving towards a more comprehensive elucidation of the mechanisms underlying viral evolution in avian coronaviruses. Such knowledge is essential for the rational design of next-generation vaccines and the development of targeted interventions to curb the spread of these economically critical pathogens [1, 2, 32].

Epidemiology and Global Impact of IBV Variants on Poultry Health

In recent decades, infectious bronchitis virus (IBV) has emerged as one of the most economically devastating pathogens affecting poultry worldwide. As an avian coronavirus belonging to the Gammacoronavirus genus, IBV causes not only respiratory diseases but also impacts the reproductive, renal, and digestive systems of chickens. The epidemiological landscape of IBV is complex, driven by its rapid mutational dynamics, recombination events, and the continual emergence of novel genotypes and serotypes that challenge current vaccination strategies [1, 12].

Geographic Distribution and Emergence of Variants

IBV variants have been reported across continents, with significant occurrences in regions such as the Middle East, North Africa, Asia, South America, and sub-Saharan Africa. For instance, studies in the Middle East and North Africa have highlighted the persistence of IBV variants despite widespread use of traditional Massachusetts vaccine strains, leading to vaccine breaks due to antigenic divergence in the S1 gene’s hypervariable regions [1]. In China, surveillance programs have revealed an intricate mosaic of genotypes, with predominant IBV strains belonging to genotypes such as GI-19 and GVI-1; these studies have also documented extensive recombination events indicating active evolution [6, 33]. Meanwhile, in regions such as Brazil and Kenya, indigenous IBV variants have been identified that exhibit unique genetic footprints, further complicating global control measures [5, 24]. The identification of unique variants in sub-Saharan Africa also underscores the necessity for continuous epidemiological monitoring, as these regions may act as reservoirs for emerging lineages [20].

Biological Mechanisms Driving IBV Evolution

The biological behavior of IBV is largely dictated by its high mutation rate and the propensity for homologous recombination, particularly in the spike protein gene. The S1 subunit of the spike protein is central to host receptor binding and carries the major epitopes for neutralizing antibodies. Frequent point mutations, insertions, deletions, and recombination events in the hypervariable regions of S1 have been extensively documented, enabling the virus to evade host immunity and reduce vaccine efficacy [1, 11]. Such molecular flexibility not only facilitates rapid antigenic drift but also permits the incorporation of genetic material from vaccine strains or heterologous field strains, ultimately resulting in novel serotypes with altered tissue tropism and pathogenicity profiles [8, 17]. This dynamic evolution is further illustrated by regional viruses that have recombined in ways that bestow distinct virulence factors, underscoring the role of selective immune pressure and adaptation to different host environments [12, 18].

Epidemiological Impact on Poultry Health and Industry

The economic ramifications of IBV infections extend far beyond acute clinical disease. Outbreaks of IBV lead to significant losses in feed conversion efficiency, egg production, and overall flock performance, thereby imposing a heavy burden on the global poultry industry. The introduction of novel IBV variants often results in clinical presentations that are atypical or more severe, as highlighted by outbreaks with multiorgan tropism where respiratory, renal, and reproductive systems are concomitantly affected [8]. In addition, the long-term shedding and persistence of certain IBV strains in poultry populations exacerbate the risk of transmission and recurrent outbreaks. Data from various surveillance studies indicate that IBV positivity rates can range widely depending on production systems and regional biosecurity measures, with retail and wholesale markets often showing higher detection rates compared to farm settings [4, 6].

The inability of traditional vaccine regimens to confer broad cross-protection against divergent IBV serotypes is a significant concern. In many countries, despite vaccination programs that employ Massachusetts-type vaccines, breakthrough infections continue to be reported because of poor antigenic matching with circulating field strains [1, 8]. This underlines the need for genotype-matched vaccines and alternative platforms such as DNA vaccines and novel nanoparticle formulations that are designed to improve cross-protection [19, 34]. In regions with high poultry density, such as parts of Asia and the Middle East, the observed rapid evolution of IBV has necessitated meta-analyses and re-evaluation of current immunization strategies by regulatory agencies such as the World Organisation for Animal Health (WOAH) and guidelines issued by the World Health Organization (WHO) on controlling zoonotic and economically critical pathogens.

Surveillance, Molecular Diagnostics, and Global Challenges

Effective control of IBV is contingent on robust surveillance systems and rapid diagnostic tools. Advances in molecular diagnostics, including RT-PCR protocols targeting conserved regions of the IBV genome, have facilitated early detection and characterization of emerging variants [13, 35]. Recent developments in point-of-care diagnostic devices, such as immunochromatographic strips, have further enhanced field surveillance capabilities, enabling rapid identification of multiple IBV genotypes in real-time [4, 13]. Such technologies are crucial for informing epidemiological models and guiding intervention strategies, particularly in resource-limited settings where comprehensive laboratory support may not be available.

From a molecular epidemiological perspective, phylogenetic analyses based on complete S1 sequences have provided valuable insights into the evolutionary relationships among IBV strains on a global scale [9, 16]. These studies reveal that the transmission dynamics of IBV are influenced by complex factors including geographical barriers, farm management practices, and interspecies transmission events. Collaborative efforts between international agencies such as the Centers for Disease Control and Prevention (CDC) and FAO have emphasized the importance of harmonized surveillance protocols, data sharing, and the development of updated vaccines to address the rapidly evolving IBV landscape.

Global Trade, Biosecurity, and Policy Considerations

The global poultry trade further complicates the epidemiological picture as the movement of live birds and poultry products across borders facilitates the spread of IBV variants. Inadequate biosecurity measures along with porous trade borders contribute to the introduction and establishment of new variants within previously unaffected regions [5, 20]. Governments and industry stakeholders are increasingly called upon by organizations like WOAH and FAO to implement stringent biosecurity policies, improve regulatory oversight, and integrate molecular epidemiology data into national disease control programs.

Moreover, the economic losses associated with IBV are not limited solely to reduced productivity but also include costs associated with increased veterinary interventions, diagnostic testing, and outbreak containment measures. The continuous evolution of IBV variants necessitates ongoing research investment to understand the interplay between viral genetics, host immunity, and environmental factors, insights that are critical for developing sustainable, long-term control strategies in the global poultry sector [12, 15].

Through integrated epidemiological surveillance and adaptive vaccination programs, the global poultry industry can better mitigate the adverse impacts of IBV. The dynamic interplay of viral evolution, global trade, and diverse farming practices underscores the urgent need for collaborative, multidisciplinary approaches to address the profound challenges posed by IBV variants on poultry health worldwide.

Molecular Diagnostics and Structural Modeling of the S1 Protein

The S1 subunit of the IBV spike glycoprotein is central to both the molecular diagnosis and structural characterization of avian coronaviruses. As the primary viral determinant responsible for host cell receptor binding, immune recognition, and antigenic variation, the S1 protein has garnered significant attention in the context of both epidemiological surveillance and vaccine design. The progressive evolution of this protein, driven by point mutations and recombination events [1, 11, 17], challenges diagnostic assays and necessitates detailed structural modeling to identify conserved neutralizing epitopes critical for cross-protection.

Molecular Diagnostics Targeting the S1 Gene

Current molecular diagnostic approaches predominantly rely on the detection and sequence analysis of the S1 gene. Reverse transcriptase polymerase chain reaction (RT-PCR) protocols, combined with nested or real-time formats, are routinely applied to field and laboratory isolates to amplify the hypervariable regions of the S1 gene [35]. These hypervariable regions harbor neutralization epitopes and are recognized as defining markers for IBV serotypes and genotypes, allowing for differentiation among numerous co-circulating variants [1, 11].

Diagnostic sensitivity is enhanced through precise primer design that targets conserved flanking regions of the S1 gene while maintaining the ability to resolve minor sequence variations among variant strains. The fine balance between specificity and the breadth of detection is vital, especially given that vaccine strains and field variants often share partial homologies. In laboratory settings, amplification products are typically subjected to cycle-sequencing methods that support subsequent phylogenetic analysis. This careful dissection of S1 nucleotide sequences not only aids in strain identification but also informs on the potential for recombination events which, as studies have shown, contribute critically to the emergence of novel IBV variants [1, 17].

Molecular diagnostic protocols developed in accordance with guidelines from international organizations such as the World Organisation for Animal Health (WOAH) and recommendations from the US Centers for Disease Control (CDC) emphasize the need for rapid, high-resolution assays. This is particularly critical given the significant economic impact of IBV on poultry, which has led to ongoing surveillance initiatives globally [1, 12]. The diagnostic platforms that integrate RT-PCR with high-resolution melting (HRM) curve analysis have demonstrated their ability to discriminate between field variants and vaccine strains with high confidence [36].

Structural Modeling of the S1 Protein

The rapid evolution of the S1 glycoprotein, with its mixture of conserved and highly variable domains, makes it an ideal candidate for detailed structural modeling. Computational approaches, exemplified by the use of the I-TASSER server and complementary meta servers [2], have provided three-dimensional models that reveal not only the overall spatial conformation of the S1 protein but also the precise location of immunogenic epitopes and glycosylation sites. This modeling is instrumental in pinpointing critical residues , for instance, studies have mapped common antigenic active sites within the hypervariable region, located at specific residues such as 229, 230, 232, 233, and 235, which are involved in stimulating neutralizing antibody responses [2, 11].

An essential aspect of structural modeling involves the evaluation of post-translational modifications, such as N-glycosylation. Analytical investigations into the glycosylation patterns of IBV spike proteins have underscored the role of conserved N-glycosylation sites in maintaining structural integrity and mediating receptor binding [7]. Through in silico docking studies conducted with available cryo-electron microscopy datasets, researchers have demonstrated that a cluster of glycosylated residues forms a ring-like structure around the receptor-binding motif. This configuration appears to stabilize the spike conformation and may influence the binding dynamics with host cell receptors, likely through an interplay with sialic acid moieties [7]. The stability and predicted accessibility of these epitopes not only inform vaccine design but also enhance the sensitivity of antigen-detection assays.

Structural modeling also provides a predictive framework for understanding the effects of point mutations and recombination events on protein structure. The dynamic nature of the S1 subunit, with its propensity for recombination [17], suggests that even single amino acid changes can potentially disrupt neutralizing epitopes or change the binding affinity to host receptors. Computational studies have allowed for the simulation of these mutational effects, thereby guiding the rational design of vaccine candidates that aim to induce broad-based immunity [2, 11]. Furthermore, the integration of molecular dynamics simulations with structural modeling techniques has advanced our understanding of how conformational flexibility in the S1 protein contributes to its ability to evade immune detection.

Integration of Diagnostics and Structural Insights

The detailed structural characterization of the S1 protein feeds directly into the optimization of molecular diagnostic platforms. For example, the identification of conserved neutralizing epitopes through modeling studies informs the design of monoclonal antibodies used in immunochromatographic assays, thereby enhancing assay specificity and cross-reactivity against divergent strains [2]. This reciprocal integration of molecular diagnostics and structural biology not only increases the diagnostic accuracy but also aids in monitoring the emergent antigenic variants that have the potential to undermine vaccination efforts.

Advanced structural models, validated by docking experiments and glycomics analysis, provide a basis for the rational design of vaccine immunogens that mimic the native conformation of the S1 protein. Such insights are vital for developing next-generation vaccines that are more effective against a broad range of IBV serotypes, especially in regions where circulating field variants differ substantially from vaccine strains [2, 7]. Regulatory frameworks guided by groups such as the World Health Organization (WHO) and the Food and Agriculture Organization (FAO) stress the critical need for updated diagnostics and vaccine intervention strategies for economically significant pathogens like IBV.

In summary, the S1 glycoprotein serves as a linchpin in both the accurate molecular diagnosis and the structural modeling endeavors aimed at curbing the impact of IBV. The continual refinement of RT-PCR based assays, enhanced by high-resolution melting and sequencing techniques, paired with the rigorous computational modeling of the S1 protein, provides a powerful combined approach. This dual strategy addresses both the current challenges in IBV diagnostics and the evolving antigenic landscape necessitated by the virus's high mutation rate, thereby offering a comprehensive approach that is integral to managing the economic and welfare impacts in the poultry industry.

Phylogenetic Relationships and Recombination Events Among Emerging IBV Strains

In recent years, the avian infectious bronchitis virus (IBV) has been intensively studied for its remarkable genetic diversity, a direct consequence of its high mutation rate and the frequent occurrence of RNA recombination events. As an RNA virus without proofreading activity in its RNA polymerase, IBV continually generates genetic variants that evolve through both point mutations and large-scale recombination events. These mechanisms not only shape the phylogenetic landscape of IBV but also challenge current vaccination strategies, as emerging strains often escape immunological recognition [1, 12, 33].

Molecular Phylogeny Based on the S1 Gene

The spike glycoprotein, and more specifically its S1 subunit, has been the focus of phylogenetic studies because it harbors the major neutralizing epitopes and exhibits high variability among strains. Early investigations using S1 gene sequence analysis demonstrated that variations in this glycoprotein correlate with distinct serotypes and genotypes of IBV [9, 11]. Phylogenetic trees constructed with full-length or partial S1 sequences reveal that IBV strains cluster into multiple genotypes (commonly designated GI, GII, etc.) with numerous sublineages. This classification, including emerging lineages such as GI-19 and GI-23, provides invaluable insights into the epidemiology and geographical dissemination of the virus [6, 16]. Studies in regions such as China and the Middle East have revealed that despite the prevalence of traditional vaccine strains like Massachusetts, novel field variants continue to appear, frequently diverging markedly from these classic genotypes [1, 6, 31].

Mechanisms and Evidence of Recombination

Recombination plays a central role in IBV evolution, facilitating the exchange of genetic material between co-circulating strains. This phenomenon has been documented extensively, with several studies demonstrating that recombination events can occur not only within the hypervariable regions of the S1 gene but also across other structural genes, such as the S2 and nucleocapsid (N) genes [17, 18]. Detailed sequence comparisons have shown that some emerging strains possess mosaic genomes combining sequences typical of vaccine strains and field isolates. For instance, cases of recombination between the Massachusetts vaccine strain and other genetically divergent strains have been documented, where portions of the S1 region, along with other genomic segments, are replaced through homologous recombination [8, 14, 17]. In one notable example, an IBV variant was found to harbor serotype-specific epitopes from both the Massachusetts and Arkansas serotypes, a testament to the virus’s ability to incorporate heterologous genomic fragments and thereby alter its antigenic profile [17].

Recent phylogenetic analyses have identified novel recombination hotspots within the IBV genome, particularly in the 5′ region of the replicase gene as well as within the hypervariable regions of the S1 gene. The identification of these recombination sites, such as the short motifs critical for template switching during replication, underscores the dynamic nature of the IBV genome [32, 38]. In some regions of the world, including parts of Africa and Asia, unique recombination events have led to the emergence of strains that bear little resemblance to classical lineages. For example, isolates from Kenya have been documented to contain recombinant spike genes resembling fragments from turkey coronaviruses on a common genome backbone shared among IBVs, suggesting cross-species recombination events might also be contributing factors [5]. Similarly, novel lineages detected in South Korea and sub-Saharan Africa reflect a complex web of recombination events that reshape the virus’s phylogenetic tree, highlighting geographic distinctions and the evolutionary pressures faced by IBV [20, 37].

Epidemiological Implications and Vaccine Challenges

The continuous generation of recombinant IBV strains has considerable implications for both epidemiology and vaccine development. Recombination events not only generate antigenically distinct variants but also alter tissue tropism and pathogenicity, leading to outbreaks that often do not respond well to existing vaccines. For instance, emerging recombinants have been associated with disparate clinical manifestations ranging from respiratory to renal and reproductive disorders. This antigenic drift and shift are critical concerns for organizations such as the World Organization for Animal Health (WOAH) and the World Health Organization (WHO), which, along with the Centers for Disease Control and Prevention (CDC), monitor zoonotic and economically significant pathogens [1, 12]. In regions like the Middle East and North Africa, despite routine vaccination with Massachusetts-type vaccines, the emergence of distinct recombinant strains has been linked to vaccine failures and significant economic losses in the poultry industry [1, 5].

The major challenge in vaccine development arises from the fact that recombination can quickly generate strains with novel antigenic determinants that are poorly neutralized by antibodies raised against earlier or vaccine strains. The rapid evolution, driven by both point mutations and recombination, means that vaccines need to be continually updated to match the circulating genotypes. Studies employing molecular modeling and cross-neutralization tests have demonstrated that some vaccine strains may confer cross-protection against genetically related variants, yet the extent of this protection is limited when confronting highly divergent recombinants [2, 8, 19]. Furthermore, the co-circulation of multiple genotypes within a single geographical region complicates the design of broad-spectrum vaccines. It is evident from phylogenetic studies that recombinant viruses often represent a blend of genetic material from two or more parental strains, which underscores the need to incorporate antigenic diversity in vaccine formulations [14, 16, 18].

Genomic Surveillance and Future Perspectives

The dynamic evolution of IBV, fueled predominantly by recombination events, necessitates rigorous and continuous genomic surveillance. Sequence-based phylogenetic studies are critical for mapping the spread and evolution of IBV and for identifying emerging lineages that may require novel intervention strategies. Such surveillance approaches involve high-resolution melting curve analysis, next-generation sequencing, and molecular clock analysis techniques, which together provide precise estimates of evolutionary rates and the timing of recombination events [6, 32, 36]. In addition, comprehensive analyses that integrate molecular findings with epidemiological data are crucial to determine the practical implications of these genetic changes in field settings.

Moreover, the detection of potential evidence of recombination between vaccine strains and circulating field viruses further highlights the importance of controlled vaccination programs and coordinated international surveillance efforts. Given that IBV can recombine both within and outside the boundaries of recognized genotypes, only an approach that combines phylogenetic analysis with protective efficacy studies, so-called protectotyping, will ultimately allow for fine-tuning of vaccination strategies to minimize the impact of these evolving pathogens [14, 23]. Such integrative strategies are essential for managing global poultry health, as recommended by international organizations like the FAO, which emphasizes the importance of proactive disease monitoring in economically critical animal industries.

These multifaceted phylogenetic and recombination analyses of IBV serve not only as a window into the virus’s evolutionary mechanisms but also as a guide in developing and updating effective vaccination protocols. The growing body of evidence, drawn from diverse geographical contexts, from China and South Korea to Africa and Brazil, illustrates that IBV is a prime example of a pathogen whose adaptability is driven by inherent genomic plasticity [16, 17, 32]. As genetic recombination continues to shape the phylogenetic framework of emerging strains, it remains imperative for researchers and vaccine developers to harness molecular insights in order to curtail the disease’s detrimental impact on poultry production worldwide.

Immunogenic Profiles and Vaccine Design Challenges in the Context of IBV Variants

Understanding the immunogenic repertoire of infectious bronchitis virus (IBV) variants is central to improving vaccine design and enhancing protection in poultry. IBV is known for its rapidly evolving antigenic structure, driven largely by mutations and recombination events in the spike protein, particularly its S1 subunit, which harbors the majority of neutralizing epitopes [1, 9, 11]. The S1 protein not only interacts with host receptors through glycosylated domains [7] but also defines serotype-specific immune responses. As the virus circulates among large poultry populations, the inherent error-prone replication of its RNA genome leads to cumulative genetic changes that complicate the establishment of robust and long-lasting immunity by existing vaccine strains.

Molecular Underpinnings of Immunogenicity in IBV

The S1 glycoprotein is the primary target for neutralizing antibodies, a feature that is exploited in vaccine development. Detailed molecular studies have mapped critical epitopes within the hypervariable regions of S1, highlighting residues whose alteration can lead to escape from neutralization [11]. Molecular modeling analyses have shown that despite structural similarities across different IBV genotypes, for example, the Massachusetts (Mass) and Italy02 strains share common active antigenic sites [2], even minor changes in the amino acid composition can have dramatic impacts on antibody recognition. This antigenic variability necessitates vaccine formulations that can either incorporate multiple epitopes or focus on conserved regions that are less prone to mutation.

The immune response to IBV is multi-faceted, involving both humoral and cellular arms. DNA vaccine strategies encapsulated within chitosan-saponin nanoparticles have demonstrated promising increases in antibody titers as well as T-cell responses, specifically CD3+ and CD8+ populations, when assessed against diverse IBV strains [34]. However, the dynamic interplay between antigen presentation and immune memory formation remains a challenge, particularly as some hypervariable epitopes undergo rapid change. These findings are corroborated by extensive phylogenetic analyses that reveal high degrees of sequence diversity in the S1 region [9, 16], underlining that an ideal IBV vaccine must contend with a spectrum of antigenic profiles.

Epidemiological Implications and Antigenic Drift

The epidemiological landscape of IBV is complicated by its capacity for recombination and genetic drift. Reports have documented the emergence of variants that are markedly different from vaccine strains currently in use [1, 27]. In several regions, such as the Middle East and North Africa [1], and more recently in China [16, 33], surveillance data illustrate that IBV strains continue to evolve beyond the antigenic coverage provided by traditional live-attenuated vaccines. This phenomenon is of particular concern as IBV can cause multi-organ tropism, affecting respiratory, renal, and reproductive systems, and spread rapidly in high-density poultry operations.

The evolutionary challenge is further exacerbated by widespread vaccination protocols that may inadvertently drive selection pressure on the virus. The phenomenon where vaccines based on the Massachusetts serotype confer suboptimal cross-protection against heterologous IBV strains has propelled the need to reassess vaccine compositions [8, 12]. In countries with intensive poultry production such as those following guidelines from WOAH or national veterinary authorities (e.g., CDC recommendations for economically critical animal pathogens), there is an urgent call for the development of vaccines that incorporate variant-specific antigens or, alternatively, broadly protective immunogens designed to overcome antigenic drift.

Vaccine Design Strategies and Challenges

One of the principal challenges in designing vaccines against IBV is the tremendous genetic and antigenic heterogeneity. Current vaccine strategies range from traditional live-attenuated and inactivated viruses to more advanced modalities such as subunit vaccines, peptide-based formulations, virus-like particles, and recombinant DNA vaccines [12]. The use of polyvalent vaccines, which combine multiple serotypes, has shown some success in extending the spectrum of protection. For instance, experimental studies in China utilizing polyvalent vaccine regimens demonstrated that combining different strains can sometimes yield protection rates exceeding 90% against prevalent QX-like strains. However, such strategies have yet to afford sufficient protection against emerging variant strains like TW-like or IBV/Variant-2 [19], indicating that not all antigenic determinants are equally immunogenic or that certain epitopes might be masked by structural changes induced by mutation or glycosylation.

A recurring challenge in vaccine design is the need to maintain the immunogenic integrity of key epitopes while avoiding potential adverse events associated with live or replicating vaccine constructs. The interplay between glycosylation patterns on the S1 protein and the exposure of neutralizing epitopes is a double-edged sword: while glycosylation is essential for structural stability and receptor binding [7], it can also obscure antigenic sites, limiting the efficacy of vaccine-induced antibodies. This necessitates fine-tuning of antigen design, whether by genetic engineering of subunit vaccine candidates or by designing nanoparticle carriers that can deliver antigens in a conformation that mimics natural infection [2, 34].

Furthermore, the rapid evolution of IBV encourages the continuous monitoring of circulating strains through advanced molecular surveillance techniques, such as full-length S1 gene sequencing and next-generation sequencing platforms [16, 32]. These approaches are indispensable for tracking the emergence of recombination events that generate novel genotypes and serotypes. The dynamic nature of IBV evolution, as evidenced by recombination between vaccine strains and field isolates [17, 18], illustrates that vaccine strains themselves can sometimes contribute to the genetic mosaic of circulating viruses, thereby complicating immunogen selection.

Integrating Immune Mechanisms with Vaccine Efficacy

Successful vaccine development against IBV must reconcile the heterogeneity of viral antigens with the host’s multifaceted immune response. Adapting vaccines to stimulate both robust neutralizing antibody responses and effective cell-mediated immunity is critical, particularly in light of data showing that delayed innate immune gene expression can result in suboptimal responses against highly pathogenic IBV strains [29]. Advanced vaccine platforms, such as replicon systems using avian hepatitis E virus that express IBV S1 antigens, are being explored to achieve potent immunogenicity while circumventing the issues of antigenic variability [39]. These innovative approaches leverage the molecular biology of RNA pathogens to ensure that the elicited immune response is broad-based and can neutralize diverse IBV variants.

In summary, the immunogenic profile of IBV is characterized by a complex and constantly evolving array of neutralizing epitopes, necessitating a continuous re-evaluation of vaccine constructs. With the economic and animal welfare implications underscored by global agencies like FAO and WOAH, addressing the challenges posed by IBV variants remains a critical priority for veterinary immunologists and vaccine designers worldwide [12, 39].

Future Perspectives and Strategic Control Measures for Avian Coronavirus Variants

The dynamic evolution of avian infectious bronchitis virus (IBV) presents a substantial challenge to both veterinary medicine and the global poultry industry. With the continuous emergence of new variants driven by point mutations, recombination events, and antigenic shifts [1, 12], future research must focus on elucidating the fundamental biological mechanisms of viral evolution to inform next-generation diagnostics and control measures. In light of reports from various parts of the world, particularly in regions with high-density poultry production such as the Middle East, Chinese commercial farms, and Europe [1, 5, 6, 16], a strategic approach is essential to contain the spread of IBV variants and reduce their economic impact.

Advanced Molecular Surveillance and Diagnostic Innovation

One of the most promising avenues for future perspectives is the integration of cutting-edge molecular surveillance techniques with rapid diagnostic platforms. The implementation of next-generation sequencing (NGS) has already uncovered novel IBV variants in understudied regions such as Eastern Africa, where complete genome analyses have revealed strains that defy the current classical genotyping frameworks [5]. Furthermore, the advent of biosensor-based diagnostic technologies, which include electrochemical, optical, and piezoelectric sensors, offers the potential for field-deployable, real-time monitoring tools that may revolutionize IBV diagnostics [10]. Rapid immunochromatographic assays, as demonstrated in recent studies [4, 13], have achieved impressive sensitivity and specificity profiles, making these tests invaluable for both outbreak detection and longitudinal surveillance programs mandated by international organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO).

Enhanced diagnostic platforms are expected to reduce the lag time between field detection and epidemiological response. In tandem with molecular diagnostics, the development of algorithms incorporating phylogenetic and antigenic data, as seen in recent comprehensive analyses [9, 15], can enable more precise mapping of IBV evolution. The integration of such tools with global data-sharing initiatives endorsed by the Centers for Disease Control and Prevention (CDC) and WHO will foster a robust framework for monitoring pathogen spread and emergence on both local and international scales.

Strategic Vaccine Design and Immunization Protocols

Despite the availability of live-attenuated and inactivated vaccines, the persistence of IBV outbreaks suggests that current immunization strategies require significant refinement. Molecular modeling studies have elucidated the spatial conformation of the S1 spike protein, which is central to eliciting neutralizing antibody responses [2]. Future vaccine development efforts are therefore likely to focus on multivalent and homologous vaccine constructs that incorporate conserved epitopes or combine components from emerging variant strains. For example, recombinant DNA vaccines encapsulated with chitosan-saponin nanoparticles have shown promise in eliciting broad immunogenicity and reducing viral shedding [34]. Such strategies could dramatically reduce the incidence of IBV infections by improving cross-protection between serotypes and genotypes, particularly in regions where multiple variants coexist [1, 12].

Strategically, vaccination programs may benefit from polyvalent vaccine combinations that are administered in heterologous prime-boost regimens [19]. These approaches seek to maximize the breadth of the immune response by targeting diverse epitopes, thereby minimizing the risk of vaccine escape variants. Moreover, the implementation of protectotyping, evaluating vaccines based on their ability to confer cross-protection against a range of circulating variants, will be critical for optimizing immunization strategies [14, 23]. In this regard, studies have already highlighted the need to adjust vaccination compositions, as the interplay between vaccine strains and field variants can influence replication dynamics and antibody responses [19].

Integrated Biosecurity and Field-Level Control

Alongside advanced molecular diagnostics and refined vaccine strategies, the future of controlling avian coronavirus variants depends on rigorous biosecurity protocols and integrated management practices. The heterogeneity of IBV variants and their capacity for widespread tissue tropism, as evidenced by variants causing respiratory, renal, and reproductive disorders [8, 24, 26], necessitate a multifaceted response. Biosecurity practices, including improved sanitation, controlled movement of poultry and poultry products, and systematic surveillance at retail and wholesale markets [4, 6], constitute the first line of defense. These measures must be supported by rapid, on-farm diagnostic tools to promptly identify and isolate outbreaks before they escalate.

Enhanced regulatory frameworks, guided by recommendations from international bodies like WOAH and supported by data-sharing platforms, will enable coordinated action across borders. Given that viruses of zoonotic concern are closely monitored by the WHO and CDC, analogous frameworks for economically critical avian pathogens could bolster both regional and global responses. Integrating epidemiological data with genetic sequencing results not only provides detailed insights into the mechanism of virus spread but also informs the development of targeted biosecurity interventions.

Future Research Initiatives and Cross-Disciplinary Collaborations

The necessity for sustained research into IBV’s evolution and control cannot be overstated. Future initiatives should aim to delineate the molecular drivers of recombination and mutation within key viral genes, especially the hypervariable regions of the S1 glycoprotein [7, 11]. A holistic research agenda, combining virological, immunological, and computational studies, is essential for mapping the intricate interactions between host immunity and viral adaptation [3, 40]. Such efforts should also explore the potential role of host genetic factors and environmental pressures that contribute to the emergence of IBV variants.

Interdisciplinary collaborations, bringing together molecular biologists, veterinary epidemiologists, immunologists, and field veterinarians, are critical for translating laboratory findings into actionable control measures [23]. Modern approaches such as replicon-based vaccine platforms, which utilize engineered viral RNA sequences to express heterologous antigens, offer exciting new directions for vaccine development while minimizing the risks associated with live virus exposure [39]. These platforms demonstrate the promise of leveraging aHEV replicons as a modular system to express immunogenic components from IBV, thus broadening the scope for next-generation vaccines.

In summary, the future perspectives for controlling avian coronavirus variants rest on a synergistic approach that combines advanced diagnostics, strategic vaccine design, stringent biosecurity measures, and expansive research collaborations. Together, these initiatives have the potential to transform our ability to predict, monitor, and control the ever-evolving landscape of IBV variants, thereby protecting poultry health and securing the economic stability of the global poultry industry.

References

[1] Khataby K, Kasmi Y, Souiri A, Loutfi C, Ennaji M. Avian Coronavirus: Case of Infectious Bronchitis Virus Pathogenesis, Diagnostic Approaches, and Phylogenetic Relationship Among Emerging Strains in Middle East and North Africa Regions. Emerging and Reemerging Viral Pathogens. 2019. DOI: https://doi.org/10.1016/B978-0-12-819400-3.00033-8

[2] Khataby K, Kasmi Y, Souiri A, Loutfi C, Ennaji M. Molecular Modeling of Major Structural Protein Genes of Avian Coronavirus: Infectious Bronchitis Virus Mass H120 and Italy02 Strains. Emerging and Reemerging Viral Pathogens. 2019. DOI: https://doi.org/10.1016/B978-0-12-814966-9.00004-4

[3] Bhuiyan MSA, Sarker S, Amin Z, Rodrigues K, Saallah S, Shaarani S, et al.. Infectious Bronchitis Virus (Gammacoronavirus) in Poultry: Genomic Architecture, Post-Translational Modifications, and Structural Motifs. Poultry. 2023. DOI: https://doi.org/10.3390/poultry2030027

[4] Zhao C, Lin L, Tang J, Zhang Y, Zhang W, Chen J, et al.. Development of a colloidal gold immunochromatographic strip for rapid detection of avian coronavirus infectious bronchitis virus. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.103648

[5] Kariithi H, Volkening J, Goraichuk I, Ateya L, Williams-Coplin D, Olivier TL, et al.. Unique Variants of Avian Coronaviruses from Indigenous Chickens in Kenya. Viruses. 2023. DOI: https://doi.org/10.3390/v15020264

[6] Wang Y, Li Y, Yu X, Wang Y, Cai C, Li W, et al.. Epidemiological surveillance of avian coronavirus in China in 2024. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105251

[7] Parsons L, Bouwman KM, Azurmendi H, Vries RDd, Cipollo J, Verheije MH. Glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding. Journal of Biological Chemistry. 2019. DOI: https://doi.org/10.1074/jbc.RA119.007532

[8] Li Y, Chen T, Lin S, Mase M, Murakami S, Horimoto T, et al.. Emerging lethal infectious bronchitis coronavirus variants with multiorgan tropism. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13412

[9] Kusters J, Niesters H, Lenstra J, Horzinek MC, Zeijst BVDvd. Phylogeny of antigenic variants of avian coronavirus IBV. Virology. 1989. DOI: https://doi.org/10.1016/0042-6822(89)90058-5

[10] Bhuiyan MSA, Gupta S, Silip JJ, Talukder S, Haque MH, Forwood J, et al.. Current trends and future potential in the detection of avian coronaviruses: An emphasis on sensors-based technologies.. Virology. 2025. DOI: https://doi.org/10.1016/j.virol.2025.110399

[11] Cavanagh D, Davis P, Mockett A. Amino acids within hypervariable region 1 of avian coronavirus IBV (Massachusetts serotype) spike glycoprotein are associated with neutralization epitopes. Virus Research. 1988. DOI: https://doi.org/10.1016/0168-1702(88)90039-1

[12] Abozeid HH. Global Emergence of Infectious Bronchitis Virus Variants: Evolution, Immunity, and Vaccination Challenges. Transboundary and Emerging Diseases. 2023. DOI: https://doi.org/10.1155/2023/1144924

[13] Liu I, Lin Y, Lin Y, Jian C, Cheng I, Chen H. A Novel Immunochromatographic Strip for Antigen Detection of Avian Infectious Bronchitis Virus. International Journal of Molecular Sciences. 2019. DOI: https://doi.org/10.3390/ijms20092216

[14] Jr. JG, Weisman Y, Ladman B, Meir R. Identification of Avian Infectious Brochitis Virus Variant Serotypes and Subtypes by PCR Product Cycle Sequencing for the Rational Selection of Effective Vaccines. . 2003. DOI: https://doi.org/10.32747/2003.7586470.bard

[15] Finger A, Ashash U, Goldenberg D, Raviv Z. Lessons learnt on infectious bronchitis virus lineage GI-23. Avian Pathology. 2024. DOI: https://doi.org/10.1080/03079457.2024.2398030

[16] Xu L, Han Z, Jiang L, Sun J, Zhao Y, Liu S. Genetic diversity of avian infectious bronchitis virus in China in recent years. Infection, Genetics and Evolution. 2018. DOI: https://doi.org/10.1016/j.meegid.2018.09.018

[17] Jia W, Karaca K, Parrish C, Naqi S. A novel variant of avian infectious bronchitis virus resulting from recombination among three different strains. Archives of Virology. 2005. DOI: https://doi.org/10.1007/BF01309861

[18] Zhang T, Han Z, Xu Q, Wang Q, Gao M, Wu W, et al.. Serotype shift of a 793/B genotype infectious bronchitis coronavirus by natural recombination. Infection, Genetics and Evolution. 2015. DOI: https://doi.org/10.1016/j.meegid.2015.03.034

[19] Shao G, Chen T, Feng K, Zhao Q, Zhang X, Li H, et al.. Efficacy of commercial polyvalent avian infectious bronchitis vaccines against Chinese QX-like and TW-like strain via different vaccination strategies. Poultry Science. 2020. DOI: https://doi.org/10.1016/j.psj.2020.06.062

[20] Bali K, Kaszab E, Marton S, Hamdiou SH, Bentaleb R, Kiss I, et al.. Novel Lineage of Infectious Bronchitis Virus from Sub-Saharan Africa Identified by Random Amplification and Next-Generation Sequencing of Viral Genome. Life. 2022. DOI: https://doi.org/10.3390/life12040475

[21] Al-Jallad T, Kassouha M, Salhab M, Alomar A, AL-Masalma M, Abdelaziz F. Molecular characterization of isolated infectious bronchitis viruses from affected vaccinated broiler flocks in Syria. BMC Veterinary Research. 2020. DOI: https://doi.org/10.1186/s12917-020-02672-1

[22] Bourogâa H, Hellal I, Hassen J, Fathallah I, Ghram A. S1 gene sequence analysis of new variant isolates of avian infectious bronchitis virus in Tunisia.. Veterinary medicine. 2012. DOI: https://doi.org/10.2147/VMRR.S32498

[23] Cook J. Letter to the Editor. Avian diseases. 2020. DOI: https://doi.org/10.1637/0005-2086-64.1.1

[24] Balestrin E, Fraga A, Ikuta N, Canal C, Fonseca A, Lunge V. Infectious bronchitis virus in different avian physiological systems, A field study in Brazilian poultry flocks. Poultry Science. 2014. DOI: https://doi.org/10.3382/ps.2014-03875

[25] Quinteros JA, Loukopoulos P, Noormohammadi A, Browning GF, Coppo M, Vaz P, et al.. Australian strains of the avian coronavirus infectious bronchitis virus predominantly target the respiratory tract rather than the kidneys in specific-pathogen-free chickens. Journal of General Virology. 2026. DOI: https://doi.org/10.1099/jgv.0.002213

[26] Mork A, Hesse M, Rahman SAE, Rautenschlein S, Herrler G, Winter C. Differences in the tissue tropism to chicken oviduct epithelial cells between avian coronavirus IBV strains QX and B1648 are not related to the sialic acid binding properties of their spike proteins. Veterinary Research. 2014. DOI: https://doi.org/10.1186/1297-9716-45-67

[27] Lv D, Dong Z, Fan W, Tang N, Wang L, Wei L, et al.. Identification of a novel avian coronavirus infectious bronchitis virus variant with three-nucleotide-deletion in nucleocapsid gene in China. Journal of Veterinary Medical Science. 2021. DOI: https://doi.org/10.1292/jvms.21-0351

[28] Abdollahi H, Rezaei-Tavirani M, Ghalyanchilangeroudi A, Maghsoudloo H, Hashemzadeh M, Hosseini H, et al.. Coronavirus: proteomics analysis of chicken kidney tissue infected with variant 2 (IS-1494)-like avian infectious bronchitis virus. Archives of Virology. 2020. DOI: https://doi.org/10.1007/s00705-020-04845-7

[29] Liu H, Wang C, He Y, Wei X, Cheng J, Yang W, et al.. Assessing a respiratory toxic infectious bronchitis virus (IBV) strain: isolation, identification, pathogenicity, and immunological failure insights. Microbiology spectrum. 2024. DOI: https://doi.org/10.1128/spectrum.03990-23

[30] Lian J, Wang Z, Xu Z, Chen T, Shao G, Zhang X, et al.. Distribution and molecular characterization of avian infectious bronchitis virus in southern China. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101169

[31] Shosha E, Abdelnaser S, Zanaty A. A full-length S1 gene sequencing of a novel emerged GI-19 and GI-23 lineages of Infectious bronchitis virus currently circulating in chicken flocks in upper Egypt reveals marked genetic diversity and recombination events. Virology Journal. 2025. DOI: https://doi.org/10.1186/s12985-025-02718-6

[32] Rohaim M, Naggar RFE, Abdelsabour MA, Mohamed MHA, El-Sabagh I, Munir M. Evolutionary Analysis of Infectious Bronchitis Virus Reveals Marked Genetic Diversity and Recombination Events. Genes. 2020. DOI: https://doi.org/10.3390/genes11060605

[33] Zhao Y, Zhang H, Zhao J, Zhong Q, Jin J, Zhang G. Evolution of infectious bronchitis virus in China over the past two decades. Journal of General Virology. 2016. DOI: https://doi.org/10.1099/jgv.0.000464

[34] Bande F, Arshad S, Bejo M, Omar A, Moeini H, Khadkodaei S, et al.. Development and immunogenic potentials of chitosan-saponin encapsulated DNA vaccine against avian infectious bronchitis coronavirus. Microbial Pathogenesis. 2020. DOI: https://doi.org/10.1016/j.micpath.2020.104560

[35] Sun J, Liu S. An RT-PCR Assay for Detection of Infectious Bronchitis Coronavirus Serotypes. Animal Coronaviruses. 2015. DOI: https://doi.org/10.1007/978-1-4939-3414-0_11

[36] Masoudian A, Sheikhi N, Bozorgmehri-Fard MH. Identification of new avian Infectious Bronchitis virus variants in Iranian poultry flocks by High Resolution Melting curve analysis. Journal of the Hellenic Veterinary Medical Society. 2018. DOI: https://doi.org/10.12681/JHVMS.16425

[37] Kim S, Kim H, Ahn S, Son S, Song J, Kim Y, et al.. Genetic, pathogenic, and antigenic characterization of GX-1, a novel infectious bronchitis virus genotype identified in South Korea. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.106217

[38] Han Z, Zhang T, Xu Q, Gao M, Chen Y, Wang Q, et al.. Altered pathogenicity of a tl/CH/LDT3/03 genotype infectious bronchitis coronavirus due to natural recombination in the 5′- 17 kb region of the genome. Virus Research. 2015. DOI: https://doi.org/10.1016/j.virusres.2015.11.021

[39] Moon H, Sung H, Park J, Kwon H. Construction of an avian hepatitis E virus replicon expressing heterologous genes and evaluation of its potential as an RNA vaccine platform. . 2021. DOI: https://doi.org/10.14405/kjvr.2021.61.e11

[40] Montassier HJ. Molecular Epidemiology and Evolution of Avian Infectious Bronchitis Virus. Brazilian Journal of Poultry Science. 2010. DOI: https://doi.org/10.1590/S1516-635X2010000200003